Aurora Spine Corporation (“Aurora Spine” or the “Company”) (TSXV: ASG) (OTCQB: ASAPF), a designer and manufacturer of innovative medical devices that improve spinal surgery outcomes, announced today that it has received “Notice of Allowance” for its patent from the United States Patent and Trademark Office (USPTO), for the invention: ‘Spinal Implant for Motion Preservation or Fusion’.
This patent covers one of Aurora Spine products in development, the ZIPFlexTM, which is a minimally invasive posterior non-fusion interspinous implant for motion preservation but can be converted to act as a fusion or non-fusion device while implanted in a patient via a small attachment.
Mr. Trent Northcutt, President and Chief Executive Officer of Aurora Spine, stated, “We are delighted to receive this Notice of Allowance from the USPTO, as it demonstrates Aurora’s commitment to designing new technologies that not only differentiate us from other mainstream products on the marketplace but build upon the company’s intellectual property and patent portfolio. This patent will allow us to commercialize new products like the ZIPFlex and increase shareholder value.”
Laszlo Garamszegi, Chief Technology Officer with Aurora Spine stated, “The Aurora Team is working hard to bolster our Intellectual Property portfolio by developing innovative spine treatment solutions to improve patient care and help patients return to everyday life as quickly as possible. This patent allowance helps Aurora widen its future product offering for the non-fusion spine surgery and develop a two-in-one solution that is currently missing from the toolbox of doctors.”